Literature DB >> 25506558

Segmental vitiligo with segmental morphea: An autoimmune link?

Pravesh Yadav1, Taru Garg1, Ram Chander1, Anita Nangia2.   

Abstract

An 18-year old girl with segmental vitiligo involving the left side of the trunk and left upper limb with segmental morphea involving the right side of trunk and right upper limb without any deeper involvement is illustrated. There was no history of preceding drug intake, vaccination, trauma, radiation therapy, infection, or hormonal therapy. Family history of stable vitiligo in her brother and a history of type II diabetes mellitus in the father were elicited. Screening for autoimmune diseases and antithyroid antibody was negative. An autoimmune link explaining the co-occurrence has been proposed. Cutaneous mosiacism could explain the presence of both the pathologies in a segmental distribution.

Entities:  

Keywords:  morphea; segmental; vitiligo

Year:  2014        PMID: 25506558      PMCID: PMC4252945          DOI: 10.4103/2229-5178.144517

Source DB:  PubMed          Journal:  Indian Dermatol Online J        ISSN: 2229-5178


  16 in total

Review 1.  New insights in segmental vitiligo: case report and review of theories.

Authors:  N van Geel; I Mollet; L Brochez; M Dutré; S De Schepper; E Verhaeghe; J Lambert; R Speeckaert
Journal:  Br J Dermatol       Date:  2011-12-14       Impact factor: 9.302

Review 2.  Vitiligo.

Authors:  S O Kovacs
Journal:  J Am Acad Dermatol       Date:  1998-05       Impact factor: 11.527

Review 3.  Frontoparietal scleroderma (en coup de sabre) following Blaschko's lines.

Authors:  Y Soma; M Fujimoto
Journal:  J Am Acad Dermatol       Date:  1998-02       Impact factor: 11.527

4.  Coincidence of vitiligo, alopecia areata, onychodystrophy, localized scleroderma and lichen planus.

Authors:  W Brenner; E Diem; F Gschnait
Journal:  Dermatologica       Date:  1979

Review 5.  Localized scleroderma is an autoimmune disorder.

Authors:  K Takehara; S Sato
Journal:  Rheumatology (Oxford)       Date:  2004-11-23       Impact factor: 7.580

6.  Simultaneous occurrence of linear scleroderma and homolateral segmental vitiligo.

Authors:  C Bonifati; G Impara; A Morrone; A Pietrangeli; M Carducci
Journal:  J Eur Acad Dermatol Venereol       Date:  2006-01       Impact factor: 6.166

7.  An investigation into the incidence of auto-immune disorders in patients with localized morphoea.

Authors:  C I Harrington; I R Dunsmore
Journal:  Br J Dermatol       Date:  1989-05       Impact factor: 9.302

8.  An uncommon presentation of the co-existence of morphea and vitiligo in a patient with chronic hepatitis B virus infection: is there a possible association with autoimmunity?

Authors:  Seçil Soylu; Ulker Gül; Müzeyyen Gönül; Arzu Kiliç; Seray Külcü Cakmak; Murat Demiriz
Journal:  Am J Clin Dermatol       Date:  2009       Impact factor: 7.403

9.  [Linear scleroderma in children (apropos of 27 cases)].

Authors:  M Larrègue; J E Ziegler; P Lauret; J Bonafe; G Lorette; A Titi; P Ramdenee; J M Bressieux
Journal:  Ann Dermatol Venereol       Date:  1986       Impact factor: 0.777

10.  Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea.

Authors:  E Antiga; P Quaglino; S Bellandi; W Volpi; E Del Bianco; A Comessatti; S Osella-Abate; C De Simone; A Marzano; M G Bernengo; P Fabbri; M Caproni
Journal:  Br J Dermatol       Date:  2010-01-22       Impact factor: 9.302

View more
  3 in total

1.  Concurrence of Circumscribed Morphea and Segmental Vitiligo: A Case Report.

Authors:  Ji Su Lee; Hyun-Sun Park; Soyun Cho; Hyun-Sun Yoon
Journal:  Ann Dermatol       Date:  2018-10-26       Impact factor: 1.444

2.  Concomitant appearance of morphea and vitiligo in a patient with autoimmune thyroiditis.

Authors:  Ahu Yorulmaz; Sevgi Kilic; Ferda Artuz; Erhan Kahraman
Journal:  Postepy Dermatol Alergol       Date:  2016-08-16       Impact factor: 1.837

Review 3.  Autoimmunity in Segmental Vitiligo.

Authors:  Reinhart Speeckaert; Jo Lambert; Vedrana Bulat; Arno Belpaire; Marijn Speeckaert; Nanja van Geel
Journal:  Front Immunol       Date:  2020-10-27       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.